Archive for the 'Vaccines' Category

FluZone Vaccine Recall Nothing to Worry About

Last week, the FDA posted notice of what appeared to be a recall of Sanofi Pasteur’s FluZone. The notice indicated that the vaccine was misbranded “due to an error in the Prescribing Information (PI) included in packages of 10 single-dose vials of Fluzone vaccine”.

There has been some buzz about it online, so I reached out to my pediatrician for more information. Upon calling my pediatrician, I was informed that the recall was not in fact a recall but simply a notice sent to doctors of a reprinting of the package insert due to a transcription error on page 8 of the insert. The vaccine has not been recalled, and the recall notice does not impact the dosage, safety or effectiveness of the vaccine.

So if you or your child received the FluZone vaccine, rest assured that it has not been recalled.

 

The notice posted on the FDA’s recall page is reproduced below:

PRODUCT
Fluzone(R), Influenza Virus Vaccine, Single-Dose Vials, 0.5 mL, NDC 49281-011-10. Recall # B-0460-12

CODE
Lot numbers U4114DA, exp 6/30/12; U4118AA, exp 6/30/12; U4118BA, exp 6/30/12; U4118BB, exp 6/30/12; U4122AA, exp 6/30/12; U4122BA, exp 6/30/12; U4122CA, exp 6/30/12; U4124AA, exp 6/30/12; U4124BA, exp 6/30/12; U4124CA, exp 6/30/12; U4147AA, exp 6/30/12; U4147BA, exp 6/30/12; U4147CA, exp 6/30/12; U4149AA, exp 6/30/12; U4159DA, exp 6/30/12; U4178AA, exp 6/30/12; U4178BA, exp 6/30/12; U4184AA, exp 6/30/12; and U4197AB, exp 6/30/12

RECALLING FIRM/MANUFACTURER
Sanofi Pasteur, Inc., Swiftwater, PA, by letter on November 14, 2011. Firm initiated recall is ongoing.

REASON
Fluzone(R), Influenza Virus Vaccine, Single-Dose Vials, 0.5mL, misbranded due to an error in the Prescribing Information (PI) included in packages of 10 single-dose vials of Fluzone vaccine, was distributed.

VOLUME OF PRODUCT IN COMMERCE
2,832,810 units

DISTRIBUTION
Nationwide

FDA Investigates Fever-Related Seizures After Flu Vaccine in Young Children

Courtesy of andyde, Flickr

The flu vaccine is making headlines this week with some disconcerting news. The FDA has issued a statement that it is investigating an increase in reports of febrile seizures (convulsions brought on by fever) in infants who received the flu vaccine, Fluzone, this flu season. Sanofi Pasteur’s FluZone is the only flu vaccine approved in the U.S. for children ages 6-23 months, so if your infant received the flu vaccine you can be certain this is the one they received. Both my daughters received it, so of course my ears perked up when I heard this news.

The FDA has said there have been 42 reports of febrile seizures as of December 13 submitted to the Vaccine Adverse Event Reporting System (VAERS), the national vaccine safety surveillance system sponsored by the FDA and the CDC which monitors possible side effects following vaccination reported by doctors, parents, or vaccine manufacturers.  38 of the reported cases occurred within 1 day of receiving the vaccine, and 36 cases were in children aged 6 months to 2 years, with 10 cases requiring hospitalization.

The FDA says each of the children have recovered and no lasting effects have been seen. While it is no doubt a serious and terrifying experience for parent and child, the National Institute of Health says that the majority of febrile seizures are short and harmless, and the main concern is preventing injury during the seizure. Most febrile seizures last a minute or two and occur during the first day of a child’s fever, generally over 102 degrees F. Approximately one in every 25 children will experience at least one febrile seizure in their lifetime, usually between the age of 6 months and 5 years with the peak being between 14 and 18 months. According to the NIH, there is no evidence that short febrile seizures cause brain damage, citing large studies which have found that children with febrile seizures have achieved normal intellectual development compared to their siblings who experienced no seizures.

The Associated Press says the FDA has been paying special attention to reports of seizures as a result of an unusually high rate of fever and febrile seizures occurring in children who received the Southern Hemisphere variant of CSL’s Afluria flu vaccine in Australia and New Zealand earlier this year. In August, the U.S. vaccine advisory panel ACIP recommended that the CSL vaccine not be given to children under 9 years old.

In this case with Fluzone, the FDA has not changed its recommendation. The vaccine is still recommended for everyone except infants under 6 months. The reports from VAERS are preliminary and have not been causally linked to the vaccine yet, but the FDA, in conjunction with Sanofi Pasteur, is looking into whether the seizures could have been caused by the vaccine and will report any new information as soon as it is available.

In the meantime, parents are left wondering what to think of this news, and I’m sure those who have not yet vaccinated their children are questioning whether to do so despite the FDA’s recommendation. To put this news into some perspective, the rate of febrile seizures following administration of the CSL vaccines was estimated at 1 per 100 doses administered among children 6 months through 4 years of age. On the other hand, we don’t have rates of incidence yet for the Sanofi vaccine. However, the CDC conducted a survey in November 2010 and estimates that approximately 44.4% of children age 6 months to 4 years were already vaccinated as of November 7th which translates into millions of doses which have already been administered (US census data for 2009 estimates over 21 million children under the age of 5). The incidence of seizures in the U.S. thus seems to be incredibly low – we’re talking 1 in hundreds of thousands. But obviously it is statistically significant enough that the FDA is looking into it, and we’ll be sure to pass along any updates.

-Jasmine

For more information regarding the flu vaccine, refer to some of our earlier posts:
FluMist Vaccine – Frequently Asked Questions
The Flu Vaccine and Your Unborn Child
What is in Your Child’s Flu Vaccine for 2010-11
AAP Issues Flu Shot Recommendations for the 2010 Flu Season

FluMist Vaccine – Frequently Asked Questions

Image courtesy Medimmune, LLC

In a previous post on the flu vaccine recommendations for this season, we shared with you the CDC’s list of who should not be vaccinated using the FluMist vaccine. For those who are considering FluMist, we thought we’d bring you answers to some frequently asked questions.

But first, a few facts:

  • Each FluMist sprayer contains a single dose which is given with one spray in each nostril.
  • It is approved for healthy people age 2-49 who are not pregnant.
  • Similar to the flu shot, it contains the three virus strains chosen for the 2010-2011 flu season, however the strains in FluMist are live but weakened versions of the virus.
  • FluMist does not contain thimerosal (mercury).

How does FluMist work?

The virus strains in FluMist are cold-adapted and temperature-sensitive meaning that they are designed to replicate or cause infection only in the cooler temperatures of the nose and throat and not in the warmer temperatures of the lower respiratory tract. The virus strains are also attenuated meaning that they’ve been weakened to the point that they’ve lost their virulence and disease-causing properties.

So once the mist is inhaled, the virus crosses the mucosal lining of the nose and replicates in the nose and throat stimulating the immune system to create protective antibodies.

What are common side effects of the vaccine?

It cannot cause the flu, but it may result in mild to moderate flu symptoms. Most common side effects include runny nose or nasal congestion. It may also cause fevers above 100°F in children 2-6 years of age and sore throats in adults. Other less common side effects reported in clinical studies include cough, chills, tiredness/weakness, and headaches.

How effective is FluMist?

Because FluMist is a live vaccine, it may produce a more effective immune response than the traditional inactivated flu vaccine. Several studies have shown this to be the case in children. The most widely cited study is one funded by Medimmune, the manufacturer of FluMist, but additional studies seem to support the conclusions in Medimmune’s study. I’ve seen figures ranging from about 45-55% reduction in flu cases compared with children who received the inactivated flu vaccine. It appears that FluMist offers better protection against both matched strains (those included in the vaccine) and mismatched strains (viruses circulating that may not match the vaccine) as well.

Interestingly, the same may not be the case for adults. A review of 3 years of data for US military personnel vaccinated against influenza found a lower incidence of influenza with the inactivated vaccine versus FluMist.

Why are certain groups not eligible to receive the vaccine?

Children under age 2 are not eligible to receive the vaccine because clinical studies showed a small but statistically significant rate of wheezing and hospitalization following immunization with the live virus. It also should not be given to individuals with asthma or children under 5 years of age with recurrent wheezing because of similar concerns and the fact that the vaccine has not been studied in people in this group. The vaccine has also not been tested on pregnant women. And finally, it is not recommended for people over age 49 because effectiveness was not demonstrated in clinical studies in this age group.

Can individuals who receive the vaccine spread it to others?

Concerns have been raised about the possible transmission of the flu virus given that FluMist is a live virus. Studies have shown that people who receive the vaccine can shed the vaccine virus after vaccination. One study in particular indicated that the majority of shedding happened within the first 3 days, and no shedding was observed after 10 days. Shedding and transmission are not synonymous, though. In a study completed by Medimmune in which approximately 200 children were followed after vaccination, transmission was observed in only one child. It’s considered an extremely rare possibility. The manufacturer estimates that the risk of getting infected with the vaccine virus after coming into contact with someone who has been recently vaccinated is approximately 0.6-2.4%. Nevertheless, the CDC recommends that people who are in close contact with immune-compromised individuals should not get the live vaccine.

If you enjoy reading PureBebe, please click on “Sign me up!” under “Email Subscription” on the right rail of the screen. By subscribing to our emails, you are telling us that you digg our site and want to read more of our baby news and topics!

Related Articles:
The Flu Vaccine and Your Unborn Child
What is in Your Child’s Flu Vaccine for 2010-11
AAP Issues Flu Shot Recommendations for the 2010 Flu Season
Death of a Hypothesis: No Link Found Between Autism and Vaccines
How to Choose the Right Pediatrician for Your Family

The Flu Vaccine and Your Unborn Child

Courtesy of bies, Flickr

If you’re pregnant right now, you’ve likely been advised by your OB to receive the flu shot. In September, the CDC along with the American College of Obstetricians and Gynecologists, the American Academy of Pediatrics, and several other medical organizations issued a letter to healthcare providers encouraging them to urge their pregnant and postpartum patients to be vaccinated.

Pregnant women are among those highest at risk for serious complications from the flu this year. And the most likely risk to the fetus is preterm delivery. Last year, pregnant women accounted for 5% of H1N1 deaths in the U.S. while only accounting for about 1% of the population. Between April and December 2009, 280 pregnant women were admitted to ICU, and of those women 56 died.

I remember some of the stories all too vividly, as I was pregnant with my second child at the time. It was definitely a frightening time as I weighed concerns over the vaccine with the risk of complications to my pregnancy. I’m sure I read every article written about H1N1 and the vaccine. Ultimately, I arrived at the conclusion that the risks associated with H1N1 outweighed any risks associated with the vaccine, and I chose to be vaccinated.

H1N1 is among the viruses expected to circulate this season and has been included in this year’s flu vaccine. In case you missed it, last week we published an article on the vaccine describing how it is made and addressing concerns over its ingredients.

The flu vaccine inserts will tell you that safety and effectiveness has not been established in pregnant women, but this is because the vaccines have not been tested on pregnant women. However, several of them have been tested on animals at doses well above human doses and results showed “no evidence of impaired fertility or harm to the fetus” and “no adverse effects on mating, female fertility, pregnancy, parturition, lactation parameters, and embryo-fetal or pre-weaning development” as well as “no vaccine-related fetal malformations”:

  • GlaxoSmithKline’s Fluarix and Flulaval were tested on rats at 56 times the human dose
  • Novartis’ Agriflu was tested on rabbits at 15 times the human dose

Each of these has, as a result, been categorized as a Pregnancy Category B drug. Pregnancy categories are used to rate the level of risk of fetal injury of a drug, if used as directed. Pregnancy Category B means that animal studies failed to show a risk and there are no well-controlled studies in women or animal studies have shown an adverse effect but adequate and well-controlled studies in women have failed to show a risk in any trimester. The remaining flu vaccines (FluZone, Fluvirin, and Afluria) have been classified as Category C because no studies have been done.

And while limited studies have been done on the flu vaccine and placental transmission, a recent study published in October has concluded that maternal vaccination can protect young infants who are too young to receive the seasonal flu vaccine. The study followed newborns born to Native American women on Navajo and White Mountain Apache Indian reservations where children have a higher rate of severe respiratory infection than the general population. Approximately half of the infants studied were born to mothers who had been vaccinated. The researchers found that infants born to influenza-vaccinated mothers had a 41% lower chance of contracting the virus and a 39% reduced risk of hospitalization from flu complications. They also found a significantly higher level of antibodies in infants born to vaccinated mothers at 2 to 3 months of age compared to infants born to unvaccinated mothers which was correlated with reduced risk of influenza through 6 months. One of the other points of interest in the study was that no difference was observed in the level of antibodies in infants whose mothers were vaccinated in different trimesters.

A companion article published with the study also notes that the findings of this study were consistent with the results of another study conducted in Bangladesh, which shows promise for vaccinating mothers against the flu as a strategy to protect fetuses and newborns.

If you enjoy reading PureBebe, please tell your friends and click on “Sign me up!” under “Email Subscription” on the right rail of the screen. By subscribing to our emails, you are telling us that you dig our site and want to read more of our healthy baby news and topics!

-Jasmine

Related Articles:
What is in Your Child’s Flu Vaccine for 2010-11
AAP Issues Flu Shot Recommendations for the 2010 Flu Season
Death of a Hypothesis: No Link Found Between Autism and Vaccines
How to Choose the Right Pediatrician for Your Family

What is in Your Child’s Flu Vaccine for 2010-11

The health decisions we make for our children are intensely personal, and I know many parents question whether the flu vaccine is safe for their children as concerns have been raised about a variety of ingredients, identified as potential toxins, included in the vaccine. I’ve spent a significant amount of time researching the 2010-2011 influenza vaccine and  would like to share that with you now.

In order to understand what is ultimately in the end product, I find it helpful to first understand the vaccine and how it is made.

The Flu Vaccine – How it is Made

Flu Strain Selection Process

Every year, the creation of the flu vaccine starts with strain selection by the WHO Global Influenza Surveillance Network. The network is made up of about 135 laboratories in 105 countries which collect samples of circulating influenza viruses and submit them to 4 WHO flu research centers for review.

Twice a year, the WHO organizes a consultation with the directors of these centers and representatives from key laboratories (Australia, UK, and US) to make a determination about which three strains it expects will be prevalent in the coming year and should be recommended for inclusion in the year’s vaccine. The decision for the Northern Hemisphere is made in February and for the Southern Hemisphere in September.

Three viruses are chosen to maximize the likelihood that the circulating viruses will be covered by the vaccine. Once the WHO has made its recommendation, each country makes their own decision for licensing of vaccines in their country. In the US, the FDA determines which viruses will be used in US-licensed vaccines.

Meanwhile, the viruses are adapted for use in manufacturing, and reference strains are then distributed by the WHO to vaccine manufacturers. The manufacturers then grow strains of the virus which are tested for potency and safety. This year, the three viruses are the 2009 H1N1 virus, the H3N2 virus, and an influenza B virus.

2010-11 Vaccines and Licensed Manufacturers

For the 2010-11 season, 8 flu vaccines have been licensed for distribution in the U.S. Not all flu vaccines are alike. While each goes through a similar manufacturing process, each does not use the same ingredients and does not necessarily have the same efficacy among different age groups.

As a result, different vaccines are approved for different age groups. They do all, however, carry the same viral strains in the same concentration. The list below has been adapted from the vaccine inserts provided by each manufacturer for the current season’s vaccines. You can click on each vaccine name for a link to the insert.

Important Note: CSL’s Afluria has been approved in the U.S. for people 6 months and up; however, its Southern Hemisphere variant of the vaccine has resulted in fever and febrile seizures in young children in Australia, primarily those under the age of 5.

The problem appears to be isolated to the Southern Hemisphere vaccine, however, ACIP (the Advisory Committee on Immunization Practices) has recommended that the Northern Hemisphere variant not be given to children under 9 years old. If no other option is available, however, providers have been advised to discuss the benefits and risks with parents. So I suggest it would be a good idea to confirm which vaccine your child is receiving.

Growth of the Virus

The vaccine is produced using fertilized hen’s eggs. According to the WHO, for most influenza vaccine production, the virus is injected into the amniotic cavity of nine to twelve day old fertilized eggs which are then incubated for two to three days while the virus multiplies.

The amniotic cavity provides a sterile, nutrient-rich environment for the growth of the virus which is then recovered by removing the amniotic fluid from the egg. Antibiotics are used in this stage to prevent bacterial growth and improve yields.

The yield of inactivated flu vaccine can range from 3-4 doses per egg, depending on the strain. I think we’re all keenly aware of the limitations of this process after last year’s H1N1 vaccine shortages. Manufacturers are looking into novel ways to grow the virus in the future.

Note: For the 2010-2011 season, Sanofi Pasteur’s Fluzone and GlaxoSmithKline’s FluLaval do not use antibiotics in the manufacturing process.

Purification and Inactivation of the Virus

After harvesting the virus containing fluids from the egg, the virus is purified (separated) and concentrated using centrifugation (rotation at high speeds to separate particles of varying density). This process uses a sucrose solution containing detergent to disrupt the viruses and separate the surface antigens from the internal proteins.

The virus is then inactivated, generally using formaldehyde or betapropiolactone, and in some cases further purified/concentrated. The Sanofi Pasteur vaccine, on the other hand, inactivates the virus before purification. And FluMist, as you know, is a live vaccine and so it is not inactivated.

Formulation and Testing of the Virus

The 3 purified strains are combined and suspended in a buffered saline solution, “buffered” meaning that it is resistant to changes in pH in order to maintain the virus and to not alter the pH of the recipient’s blood after injection.

The combined virus is then tested by the manufacturer and the FDA to ensure the proper amount of virus and then released for distribution. It is packaged in either pre-filled single-dose syringes, multi-dose vials or, in the case of Flu Mist, nasal sprayers.

Thimerosal is added to multi-dose vials as a preservative to prevent contamination when multiple doses are drawn from the same vial. Each lot is sealed, inspected, labeled, and then formally released by the FDA.

So What’s in the End Product?

I’ve prepared a 2010-11 U.S. Flu Vaccine Information Chart from the package inserts of each vaccine which identifies the ingredients according to their purpose and lists the amounts remaining in the end product.

Ultimately, the vaccine contains the virus suspended in a saline solution, with trace amounts of the egg proteins, antibiotics, detergents, and inactivating agents used during the creation of the vaccine.

Antibiotics

Because antibiotics such as penicillin can result in severe allergic reactions in children sensitive to them, some parents are concerned about possible adverse reactions but the types of antibiotics more likely to cause such reactions are not included in vaccines. The antibiotics that are used are reduced to very small amounts through the subsequent purification steps.

Detergents

Detergents used in the production of the flu vaccine include octylphenol ethoxylate (TRITON X-100) and polysorbate 80.

Another name for octylphenol ethoxylate is polyethylene glycol which is sometimes confused with ethylene glycol, a compound widely used in automotive antifreeze. The two are related, but they have very different effects on the human body. Polyethylene glycol is a much larger molecule than ethylene glycol, not easily absorbed by the body. Polyethylene glycol is actually considered to have a low toxicity and is often used in a variety of products such as laxatives, skin creams, toothpaste, and lubricants.

Polysorbate 80  is not just used in vaccines but is also in our foods. It is used as an emulsifier, particularly in ice cream to make it smoother and easier to handle and increase its resistance to melting. One study of the possible effects of polysorbate 80 concluded that when baby female rats were injected with the chemical, it caused early maturation and changes in their reproductive organs, leading to claims of infertility.

However, Dr. David Gorski of www.sciencebasedmedicine.org highlights the fact that this study used levels of the chemical at incredibly high proportions to the rat’s body weight, much higher than levels we consume on a daily basis in food (approx .1g) which in turn is much greater than levels found in the flu vaccine (.415mg). In addition, a number of other similar studies concluded the exact opposite – that the chemical did not result in any abnormal changes.

Inactivating Agents

Formaldehyde is the inactivating agent that gets the most attention. It is a colorless, flammable chemical with a strong smell that can cause a burning sensation to the eyes, nose, and lungs at high concentrations. It has been classified as a known human carcinogen by the International Agency for Research on Cancer (IARC) and a probable human carcinogen by the EPA.

A number of studies have demonstrated the link between exposure and cancer, primarily of the nose and throat. It seems the danger is in prolonged direct contact through the air or consumption in extremely high concentrations. It can be found in the air we breathe, the food we eat, the carpet and furniture in our homes, but is also naturally occurring in our own bodies.

According to the Department of Health and Human Services’ (DHHS) Toxicology Profile on Formaldehyde, it is produced in small amounts by most living organisms as part of our normal metabolic processes and, in that respect, causes us no harm.  DHHS also says that it is easily absorbed when we breathe it in or eat/drink it, and once absorbed it breaks down very quickly and there are a number of ways our bodies can get rid of it or use it.

Almost every tissue in the body has the ability to break it down, and it is usually converted to a non-toxic chemical called formate, which is then excreted in the urine. It can also be converted to carbon dioxide and breathed out. Or it can be broken down so our bodies can use it to make larger molecules needed in our tissues.

An article published by the Children’s Hospital of Philadelphia says that humans have about 2.5 mcg of natural formaldehyde per ml of blood, which for an average weight 2-month-old infant translates to about 1.1mg of formaldehyde, a value at least five times greater than that to which an infant would be exposed in vaccines. The article also goes on to say that quantities of formaldehyde at least 600 times greater than that contained in vaccines has been given safely to animals.

Thimerosal

Thimerosal is a mercury-based preservative, 49.6% mercury by weight, which has been the primary cause of many parents’ concern because mercury can affect brain development and the nervous system.

Because of these concerns, policy makers in the United States took steps in 1999 to reduce infant exposure to thimerosal by recommending that it be reduced to trace amounts or eliminated from infant vaccines altogether.  All routine vaccinations for children 6 and under now contain no or trace amounts of thimerosal, except for the influenza vaccine.

It’s important to distinguish, though, between ethylmercury and methylmercury. Thimerosal breaks down into ethylmercury, a related but distant chemical from methylmercury.  At the time that the policy decision was made, not much was known about ethylmercury so decisions were made based on what we knew about methylmercury, which was well established as a neurotoxin that accumulates in the food chain and subsequently in our bodies when we consume foods containing it.

It distributes easily throughout the body, including the brain and is eliminated very slowly thus building up with prolonged/repeated exposure. Methylmercury poisoning has resulted in neurological damage and death. Ethylmercury, on the other hand, has since been studied and we have learned that, while ethylmercury distributes through the body just as easily, it is eliminated from the body much more quickly.

In fact, in a study of healthy infants, pre and post vaccination blood and stool samples were taken from newborns, 2- and 6- month old infants and it was determined that ethylmercury did not appear to accumulate, that the half-life of mercury from the blood was approximately 3.7 days, and that ethylmercury was much more rapidly excreted than methylmercury.

Another major concern over thimerosal takes things a step further with suggested links to autism, but this theory has, as of late, received a lot of attention to the contrary. In fact, you may have read our post “Death of a Hypothesis: No Link Found Between Autism and Vaccines” regarding the Lancet medical journal’s decision to retract the paper that started it all. Several research studies or reviews of data have shown that while thimerosal has been removed from childhood vaccines, autism rates continue to go up…so we’re still in search of an answer.

If you are still uncomfortable with thimerosal in the flu vaccine, refer to my 2010-11 U.S. Flu Vaccine Information Chart to see which single-dose prefilled syringes are available without thimerosal and ask your doctor.

Please leave us a comment, and let us know your thoughts on the flu vaccine. Will your child be vaccinated?

-Jasmine

If you enjoy reading PureBebe, please click on “Sign me up!” under “Email Subscription” on the right rail of the screen. By subscribing to our emails, you are telling us that you digg our site and want to read more of our baby news and topics!

AAP Issues Flu Shot Recommendations for the 2010-2011 Flu Season

Image courtesy epmonthly.com

Yesterday, the American Academy of Pediatrics released its recommendations for this year’s seasonal flu vaccine.  They recommend that all children and adolescents over 6 months of age be vaccinated as well as anyone falling in one of the following high-risk groups (which appear to be consistent with the H1N1 high risk groups from last year):

  1. Children younger than 5 (and according to the CDC especially children younger than 2)
  2. Children with high-risk conditions such as asthma, diabetes, or neurologic disorders
  3. People who live with or care for those at high risk – family members, health care workers, and day care providers
  4. Pregnant women

The seasonal flu vaccine protects against the three flu viruses that scientists expect will be the most common during the upcoming season. This year, the seasonal flu vaccine will protect against the 2009 H1N1 virus, the H3N2 virus, and an influenza B virus and will be available in three forms:

  1. Nasal spray flu vaccine, also referred to as FluMist or “live attenuated influenza vaccine”
  2. Inactivated flu vaccine
  3. Preservative-free inactivated flu vaccine (thimerosal-free)

Thimerosal is a mercury-containing organic compound used as a preservative to prevent bacterial contamination in vaccine vials that contain multiple doses. Some parents have concerns about the use of thimerosal in vaccines, so many pediatric offices offer the thimerosal-free single dose injections for children under 3. Anyone over the age of 3 interested in the preservative-free vaccine should consider the FluMist vaccine assuming they don’t meet any of the criteria below.

According to the CDC, the following people should not receive the FluMist vaccine:

  • People less than 2 years of age
  • People 50 years of age and over
  • People with a medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airways disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.
  • Children <5 years old with a history of recurrent wheezing
  • Children or adolescents receiving aspirin
  • People with a history of Guillain–Barré Syndrome that occurred after receiving influenza vaccine
  • Pregnant women
  • People who have a severe allergy to chicken eggs or who are allergic to any of the nasal spray vaccine components.

Now, here’s where it gets tricky. The number of doses depends on the child’s age at the time of the first dose and their vaccine history for both seasonal and H1N1 vaccines:

  • Children younger than 6 months are too young to receive influenza vaccine.
  • Children 9 years of age and older need only 1 dose.
  • Children younger than 9 years need a minimum of 2 doses of 2009 pandemic H1N1 vaccine. If they did not receive the H1N1 vaccine during last year’s flu season, they will need two doses of seasonal influenza vaccine this year.
  • Children younger than 9 years who have never received the seasonal flu vaccine before will need 2 doses.
  • Children younger than 9 years who received seasonal flu vaccine before the 2009-2010 flu season need only one dose this year if they received at least 1 dose of the H1N1 vaccine last year. They need 2 doses this year if they did not receive at least 1 dose of the H1N1 vaccine last year.
  • Children younger than 9 years who received seasonal flu vaccine last year for the first time, but only received 1 dose, should receive 2 doses this year.
  • Children younger than 9 years who received a flu vaccine last year, but for whom it is unclear whether it was a seasonal flu vaccine or the H1N1 flu vaccine, should receive 2 doses this year.
  • All children who need 2 doses should receive the second dose at least 4 weeks after the first dose.

Did you catch that?? Sheesh. To attempt to put it in easier terms, children between the ages of 6 months and 9 years will need 2 doses, 4 weeks apart, unless they have received:

  1. at least 1 dose of 2009 H1N1 vaccine last flu season, and
  2. at least 1 dose of seasonal flu vaccine before the 2009-2010 flu season or 2 doses of seasonal flu vaccine last flu season.

So it appears my two year old will need only one dose since she received two doses of the H1N1 vaccine last season and at least 1 dose of seasonal flu vaccine before last season. She only received 1, not 2 doses, of seasonal flu vaccine last year.

Fortunately, the AAP recognizes that this is confusing and says that it has created a concise flow chart to help you determine the required number of doses. The flow chart should be published in the October 2010 issue of Pediatrics with its policy statement on flu vaccination. We’ll plan to post it once we can get our hands on it. In the meantime, it’s probably best to review your child’s vaccination history and consult your pediatrician.

Please leave us a Comment and let us know your thoughts!

If you enjoy reading PureBebe, please click on “Sign me up!” under “Email Subscription” on the right rail of the screen. By subscribing to our emails, you are telling us that you digg our site and want to read more of our baby news and topics!

-Jasmine




Sharing Buttons by Linksku